European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin

RegulatoryasedebartPositive

AI Analysis

Summary

The European Commission granted orphan designation for asedebart (Lu AG13909), Lundbeck's investigational anti-ACTH monoclonal antibody for treating Cushing's syndrome of endogenous origin, a rare endocrine disorder.

Outcome Details

European Commission granted orphan designation

Importance:6/10

Sentiment:

0.70

orphan_designationmonoclonal_antibodyrare_diseaseendocrinologyregulatory_milestone

Related Companies

$HLUYY

Read the original article

Published by PR Newswire Biotech on August 24, 2026 9:35 AM

Read Original